Pasar al contenido principal

MONITORIZACION SIMULTANEA DE CELULAS LEUCEMICAS Y DEL SISTEMA INMUNE CIRCULANTES EN LEUCEMIA AGUDA LINFOBLÁSTICA DE PRECURSORES B DEL ADULTO MEDIANTE NGF DE >25 COLORES: IMPACTO PRONOSTICO.

PI19/01183

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION DE INVESTIGACION DEL CANCER
Centro realización CENTRO DE INVESTIGACION DEL CANCER -IBMCC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

  • González Gil, Celia|||0000-0002-7582-1482
  • Morgades, Mireia|||0000-0003-0295-2534
  • Lopes, Thaysa|||0000-0003-1522-6312
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Hermosín, Lourdes
  • Maluquer, Clara
  • González Campos, José
  • Bernal, Teresa|||0000-0002-2338-513X
  • Arriaga, Marta Sitges
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Larrayoz, María José
  • Artola, Teresa
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Tormo, Mar|||0000-0001-9622-1649
  • Gil, Cristina
  • Novo, Andrés
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Queipo, María-Paz
  • González-Martínez, Teresa
  • Cabrero, Mónica
  • Cladera, Antonia
  • Cervera, José|||0000-0001-8252-1106
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis

  • Isidro-Hernández, Marta
  • Mayado, Andrea
  • Casado-García, Ana
  • Martínez-Cano, Jorge
  • Palmi, Chiara
  • Fazio, Grazia
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Raboso-Gallego, Javier
  • Blanco, Óscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Jiménez, Rafael|||0000-0003-4103-8219
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
PAX5 is one of the most frequently mutated genes in B-cell acute lymphoblastic leukemia (B-ALL), and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. Abnormal profiles of inflammatory markers have been detected in neonatal blood spot samples of children who later developed B-ALL. However, how inflammatory signals contribute to B-ALL development is unclear. Here, we demonstrate that Pax5 heterozygosis, in the presence of infections, results in the enhanced production of the inflammatory cytokine interleukin-6 (IL-6), which appears to act in an autocrine fashion to promote leukemia growth. Furthermore, in vivo genetic downregulation of IL-6 in these Pax5 heterozygous mice retards B-cell leukemogenesis, and in vivo pharmacologic inhibition of IL-6 with a neutralizing antibody in Pax5 mutant mice with B-ALL clears leukemic cells. Additionally, this novel IL-6 signaling paradigm identified in mice was also substantiated in humans. Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5-dependent B-ALL and the IL6 as a therapeutic vulnerability for B-ALL characterized by PAX5 loss.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

  • González Gil, Celia|||0000-0002-7582-1482
  • Morgades, Mireia|||0000-0003-0295-2534
  • Lopes, Thaysa|||0000-0003-1522-6312
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • García-Chica, Jesús
  • Zhao, Ran
  • Montesinos, Pau|||0000-0002-3275-5593
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Coll, Rosa|||0000-0003-0560-1254
  • Hermosín, Lourdes
  • Mercadal, Santiago|||0000-0003-4741-7885
  • González Campos, José
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Artola, Teresa
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Tormo, Mar|||0000-0001-9622-1649
  • Gil, Cristina
  • Barba, Pere|||0000-0001-7076-7969
  • Novo, Andrés
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Bernal, Teresa|||0000-0002-2338-513X
  • de Ugarriza, Paula López
  • Queipo, María-Paz
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Giménez, Alicia
  • González-Martínez, Teresa
  • Cladera, Antonia
  • Cervera, José|||0000-0001-8252-1106
  • Fernández-Martín, Rosa
  • Ardaiz, María Ángeles
  • Vidal, María Jesús
  • Baena, Ángela
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Maciejewski, Jaroslaw|||0000-0002-6837-4346
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. Few genetic markers are associated with the outcome of T-ALL patients, independently of measurable residual disease (MRD) status after therapy. In addition, the prognostic relevance of genetic features may be modulated by the specific treatment used. We analyzed the genetic profile of 145 T-ALL patients by targeted deep sequencing. Genomic information was integrated with the clinical-biological and survival data of a subset of 116 adult patients enrolled in two consecutive MRD-oriented trials of the Spanish PETHEMA (Programa Español de Tratamientos en Hematología) group. Genetic analysis revealed a mutational profile defined by DNMT3A/ N/KRAS/ MSH2/ U2AF1 gene mutations that identified refractory/resistant patients. Mutations in the DMNT3A gene were also found in the non-leukemic cell fraction of patients with T-ALL, revealing a possible mutational-driven clonal hematopoiesis event to prime T-ALL in elderly. The prognostic impact of this adverse genetic profile was independent of MRD status on day +35 of induction therapy. The combined worse-outcome genetic signature and MRD on day +35 allowed risk stratification of T-ALL into standard or high-risk groups with significantly different 5-year overall survival (OS) of 52% (95% confidence interval: 37-67) and 17% (95% confidence interval: 1-33), respectively. These results confirm the relevance of the tumor genetic profile in predicting patient outcome in adult T-ALL and highlight the need for novel gene-targeted chemotherapeutic schedules to improve the OS of poor-prognosis T-ALL patients.